Etoposide plus carboplatin admixture : phase I study of five- or seven-day continuous infusion

Thirty-five patients were entered in a Phase I trial of an admixture infusion of etoposide (VP-16) and carboplatin (CBDCA) administered continuously for 5 or 7 days. Because of the compatibility and solubility of the two agents, the treatment program could be administered on an outpatient basis. The dose rate of VP-16 was fixed at 30 mg/m 2 /day (total dose 150 mg/m 2 for 5 days or 210 mg/m 2 for seven days) for each cycle. Carboplatin was evaluated at three dose rates: 5O, 60, and 75 mg/m 2 /day on the 5-day infusion and 40, 5O, and 60 mg/m 2 /day on the 7-day infusion with cycles repeated at 28 to 42 days